疫苗衍生脊髓灰质炎病毒暴发最新进展——全球,2021年1月至2022年12月
本文报告2021年1月至2022年12月全球cVDPV暴发情况:共88起活跃暴发,其中76起(86%)由cVDPV2引起,波及46个国家;2020—2022年麻痹性cVDPV病例总数从1117例降至715例(下降36%),但cVDPV1病例占比从2020年3%升至2022年18%。
要点
- 2021—2022年全球有88起活跃cVDPV暴发,76起(86%)为cVDPV2。
- 暴发波及46国,17国(37%)报告切换后首起cVDPV2暴发。
- 2020—2022年麻痹性cVDPV病例从1117例降至715例(降36%),cVDPV1占比从3%升至18%。
核心结论
- 2021—2022年全球cVDPV暴发以cVDPV2为主,麻痹性cVDPV病例总数下降但cVDPV1占比上升,需提高常规免疫覆盖率、加强脊灰病毒监测并及时开展高质量补充免疫活动以阻断传播。
研究设计与样本
- 本文为全球cVDPV暴发监测数据的描述性更新报告,数据截至2023年2月14日。
主要发现
- 2021—2022年共有88起活跃cVDPV暴发,其中76起(86%)由cVDPV2引起。
- cVDPV暴发波及46个国家,其中17个(37%)报告了切换后首起cVDPV2暴发。
- 2020—2022年麻痹性cVDPV病例总数从1117例降至715例,下降36%。
- cVDPV1病例占所有cVDPV病例的比例从2020年3%升至2022年18%,包括两国出现cVDPV1与cVDPV2同时流行。
- cVDPV1病例占比上升与COVID-19大流行期间(2020—2022年)全球常规免疫覆盖率大幅下降及预防性免疫活动暂停有关,部分国家暴发应对也不理想。
临床怎么用
- 原文提出需提高常规免疫覆盖率、加强脊灰病毒监测,并针对cVDPV暴发及时开展高质量补充免疫活动,以阻断cVDPV传播并实现2024年无cVDPV分离的目标。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Circulating vaccine-derived poliovirus (cVDPV) outbreaks* can occur when oral poliovirus vaccine (OPV, containing one or more Sabin-strain serotypes 1, 2, and 3) strains undergo prolonged circulation in under-vaccinated populations, resulting in genetically reverted neurovirulent virus (1,2). Following declaration of the eradication of wild poliovirus type 2 in 2015 and the global synchronized switch from trivalent OPV (tOPV, containing Sabin-strain types 1, 2, and 3) to bivalent OPV (bOPV, containing types 1 and 3 only) for routine immunization activities† in April 2016 (3), cVDPV type 2 (cVDPV2) outbreaks have been reported worldwide (4). During 2016-2020, immunization responses to cVDPV2 outbreaks required use of Sabin-strain monovalent OPV2, but new VDPV2 emergences could occur if campaigns did not reach a sufficiently high proportion of children. Novel oral poliovirus vaccine type 2 (nOPV2), a more genetically stable vaccine than Sabin OPV2, was developed to address the risk for reversion to neurovirulence and became available in 2021. Because of the predominant use of nOPV2 during the reporting period, supply replenishment has frequently been insufficient for prompt response campaigns (5). This report describes global cVDPV outbreaks during January 2021-December 2022 (as of February 14, 2023) and updates previous reports (4). During 2021-2022, there were 88 active cVDPV outbreaks, including 76 (86%) caused by cVDPV2. cVDPV outbreaks affected 46 countries, 17 (37%) of which reported their first post-switch cVDPV2 outbreak. The total number of paralytic cVDPV cases during 2020-2022 decreased by 36%, from 1,117 to 715; however, the proportion of all cVDPV cases that were caused by cVDPV type 1 (cVDPV1) increased from 3% in 2020 to 18% in 2022, including the occurrence of cocirculating cVDPV1 and cVDPV2 outbreaks in two countries. The increased proportion of cVDPV1 cases follows a substantial decrease in global routine immunization coverage and suspension of preventive immunization campaigns during the COVID-19 pandemic (2020-2022) (6); outbreak responses in some countries were also suboptimal. Improving routine immunization coverage, strengthening poliovirus surveillance, and conducting timely and high-quality supplementary immunization activities (SIAs) in response to cVDPV outbreaks are needed to interrupt cVDPV transmission and reach the goal of no cVDPV isolations in 2024.
引用
- Bigouette JP, Henderson E, Traoré MA, et al. Update on Vaccine-Derived Poliovirus Outbreaks - Worldwide, January 2021-December 2022. MMWR Morb Mortal Wkly Rep. 2023. PMID: 37022974. doi:10.15585/mmwr.mm7214a3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。